Single-center retrospective cohort study of antiangiogenic therapy in patients with advanced SMARCA4-deficient thoracic tumor

SMARCA4 (BRG1)-deficient tumors (SDTTs) are frequently diagnosed at an advanced stage and have poor prognosis. A retrospective cohort study at Sun Yat-sen University Cancer Center (Guangzhou, China) evaluated inclusion of anti-angiogenic therapy in first-line treatment of advanced SDTTs. Among 151 enrolled patients, 49 received antiangiogenic therapy and 102 patients did not. The ORR and DCR of first-line therapy with antiangiogenic therapy was 51.4% and 86.5%, respectively, compared to only 37.1% and 78.7% without antiangiogenic therapy; the median PFS was 7.97 versuys 5.87 months (HR 0.612; p=0,043). For patients who did not receive immune checkpoint inhibitors, the median PFS was 5.10 months with antiangiogenic therapy plus chemotherapy versus 2.57 months with chemotherapy alone (HR 0.365; p=0.043). Among patients receiving ICI plus chemotherapy, addition of antiangiogenic therapy was associated with median PFS 11.90 months compared with 6.90 months without antiangiogenic therapy (HR 0.294; p=0.013). The authors conclude that inclusion of antiangiogenic therapy in first-line treatment of advanced SDTTs was associated with promising outcomes.